"""
Question: 1101

Evidence: The study was approved by the Ethics Committee of Monza-Brianza province, Lombardy, Italy, for the coordinating center, San Gerardo Hospital, on 12 June 2014, with reference no. 1893 (authorised by Decree 93, 19 June 2014). It was then approved by the EC of each participating center. It was conducted according to the declaration of Helsinki principles. Participants gave informed consent to participate in the study before taking part.

Rationale: The paper describes a retrospective analysis of data and sequences collected from patients diagnosed with acute or early HIV-1 infection across clinical centres in Italy. The study was approved by ethics committees and participants gave informed consent, indicating this is a report of original research involving human subjects. There is no mention of this data having been published previously.

Answer: Yes
"""

"""
Question: 1102

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing. A phylogenetic tree was constructed encompassing all 186 sequences ( online supplemental figure 1 ).

Rationale: The paper explicitly states that pol sequences were obtained for drug resistance testing and that a phylogenetic analysis was performed using these sequences. The construction of a phylogenetic tree with 186 sequences confirms that HIV sequences are a central component of the reported research.

Answer: Yes
"""

"""
Question: 1103

Evidence: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-­ for-­ profit sectors.

Rationale: I have reviewed the entire paper content, including the methods and results sections. There is no description of any in vitro passage experiments being conducted. The study is focused on the analysis of sequences from primary HIV-1 infections in patients.

Answer: No
"""

"""
Question: 1104

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing. Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list.

Rationale: The paper reports on genotypic drug resistance testing (identifying mutations), but it does not describe any experiments to test viral susceptibility to antiretroviral drugs in cell culture (in vitro). The resistance data is based on sequence analysis, not phenotypic assays.

Answer: No
"""

"""
Question: 2101

Evidence: Pol sequences were aligned with full-length reference sequences retrieved from the LANL database ( https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html ) using Clustal X.

Rationale: The paper mentions using reference sequences from the LANL database for alignment and subtyping. However, there is no mention of the authors depositing their own newly generated sequences into GenBank or reporting any GenBank accession numbers for the sequences obtained in this study.

Answer: No
"""

"""
Question: 2102

Evidence: Pol sequences were aligned with full-length reference sequences retrieved from the LANL database ( https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html ) using Clustal X.

Rationale: The paper does not report any GenBank accession numbers, neither for laboratory HIV isolates nor for any other sequences. It only references the use of sequences from the LANL database for comparative analysis.

Answer: No
"""

"""
Question: 2103

Evidence: Pol sequences were aligned with full-length reference sequences retrieved from the LANL database ( https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html ) using Clustal X.

Rationale: The paper does not list or mention any specific GenBank accession numbers for the sequences generated in this study. It only refers to a public database (LANL) used for obtaining reference sequences.

Answer: NA
"""

"""
Question: 2202

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with the additional RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I.

Rationale: The paper provides a list of specific drug resistance mutations that were screened for (the WHO 2009 list plus additional RT mutations). However, it does not provide a list of which specific mutations were found in each individual sequenced isolate; it only reports the overall prevalence of TDR (16/186 participants).

Answer: No
"""

"""
Question: 2301

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). A diversity of non-­ B subtypes accounted for 60/186 (32.3%) of all infections.

Rationale: The paper exclusively studies HIV-1, as stated in the title ("HIV-1 infections"), abstract, and throughout the text. There is no mention of HIV-2 or any other HIV species.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: Molecular subtyping showed that clade B accounted for 67.7% sequences. The most common non-B clades were CRF02_AG (21/186, 11.3%), F1 (17/186, 9.1%) and C (7/186, 3.8%). Other non-B clades were CRF18_cpx, CRF01_AE, G, A1, CRF12_BF, CRF19_cpx and CRF28_BF.

Rationale: The results section provides a detailed breakdown of the subtypes found in the study population. The subtypes identified are B, CRF02_AG, F1, C, CRF18_cpx, CRF01_AE, G, A1, CRF12_BF, CRF19_cpx, and CRF28_BF.

Answer: B, CRF02_AG, F1, C, CRF18_cpx, CRF01_AE, G, A1, CRF12_BF, CRF19_cpx, CRF28_BF
"""

"""
Question: 2303

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The methods section explicitly states that the gene sequenced was pol, which includes the full-length protease and a defined region of the reverse transcriptase.

Answer: pol
"""

"""
Question: 2304

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing. A phylogenetic tree was constructed encompassing all 186 sequences.

Rationale: The entire study is based on the analysis of HIV pol sequences obtained from participants. The sequences were used for subtyping, phylogenetic analysis (transmission clustering), and drug resistance evaluation.

Answer: Yes
"""

"""
Question: 2401

Evidence: Among 186 individuals with PHI, 153 (82.3%) were from cities in the north of Italy (Milan: 54, Brescia: 38, Monza: 20, Bergamo: 16, Modena: 22, Genoa: 3); 26 (14.0%) from Rome; and 7 (3.8%) from Sardinia (Sassari 2) and Sicily (Catania 5).

Rationale: The paper provides a detailed geographic breakdown of where the study participants were from within Italy. The sequences are from multiple cities across northern, central, and southern Italy, including islands.

Answer: Italy (specifically cities in the north: Milan, Brescia, Monza, Bergamo, Modena, Genoa; center: Rome; and islands: Sardinia, Sicily)
"""

"""
Question: 2402

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI)... who were diagnosed in 2008–2014. Year of diagnosis (years), median (IQR): 2012 (2011–2014).

Rationale: The introduction states the study collected data from patients diagnosed in 2008–2014. Table 1 further specifies that the median year of diagnosis for the cohort was 2012, with an interquartile range from 2011 to 2014.

Answer: 2008-2014
"""

"""
Question: 2502

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The methods section explicitly states that Sanger sequencing was the technology used to obtain the pol sequences for all participants.

Answer: Yes
"""

"""
Question: 2503

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper specifies that Sanger sequencing was used. There is no mention of Next-Generation Sequencing (NGS) technologies being used for sequencing in this study.

Answer: No
"""

"""
Question: 2504

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper describes the use of standard Sanger sequencing on plasma samples. There is no mention of samples undergoing a cloning step prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The methods describe standard population-based Sanger sequencing. There is no description of a single genome sequencing (SGS) or single genome amplification (SGA) protocol, which would be necessary to ensure sequences are from a single viral genome.

Answer: No
"""

"""
Question: 2506

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper describes direct sequencing of PCR products from plasma virus. There is no mention of inserting viral genetic material into a vector (molecular cloning) for sequencing.

Answer: No
"""

"""
Question: 2601

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The methods section explicitly states that all genotyping was performed on plasma samples.

Answer: Yes
"""

"""
Question: 2602

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The paper specifies that sequencing was performed on plasma. There is no mention of sequencing being performed on DNA from PBMCs or the proviral reservoir.

Answer: No
"""

"""
Question: 2603

Evidence: The PHI cohort comprised 186 participants. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The study cohort consisted of 186 participants, and it is explicitly stated that all genotypic analyses were performed on plasma samples. Therefore, all 186 samples underwent plasma virus sequencing.

Answer: 186
"""

"""
Question: 2604

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The paper clearly states that all sequencing was done from plasma. There is no report of any sequencing from PBMCs.

Answer: 0
"""

"""
Question: 2605

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI), defined as detectable plasma HIV-1 RNA. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The participants had primary HIV infection with detectable plasma HIV-1 RNA, indicating active viral replication. Sequencing was performed directly from this plasma, meaning the sequences are from replicating virus.

Answer: Yes
"""

"""
Question: 2606

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The paper explicitly states that sequencing was from plasma, which contains cell-free virus. It does not mention sequencing from cellular DNA (proviral DNA) from PBMCs or any other reservoir.

Answer: No
"""

"""
Question: 2701

Evidence: The PHI cohort comprised 186 participants (159/186, 85.5% males) with median age 44 years.

Rationale: The median age of the participants was 44 years, which is an adult population. There is no mention of infants, children, or adolescents being included in the study cohort.

Answer: No
"""

"""
Question: 2702

Evidence: Italian Network of Acute HIV Infection is a nationwide, multicentre cohort study that up to 2014 collected data and viral genome sequences from patients diagnosed with acute or early HIV-­ 1 infection across clinical centres in Italy.

Rationale: The paper describes a prospective cohort study, not a clinical trial. Participants were diagnosed and followed in a standard clinical care setting, not as part of an interventional trial.

Answer: No
"""

"""
Question: 2703

Evidence: Italian Network of Acute HIV Infection is a nationwide, multicentre cohort study that up to 2014 collected data and viral genome sequences from patients diagnosed with acute or early HIV-­ 1 infection across clinical centres in Italy.

Rationale: As this is an observational cohort study and not a clinical trial, none of the individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: The PHI cohort comprised 186 participants. A phylogenetic tree was constructed encompassing all 186 sequences.

Rationale: The study population consisted of 186 individuals with primary HIV infection, and phylogenetic analysis was performed on sequences from all 186 participants. Therefore, samples were obtained from all 186 individuals for sequencing.

Answer: 186
"""

"""
Question: 3102

Evidence: The PHI cohort comprised 186 participants. A phylogenetic tree was constructed encompassing all 186 sequences.

Rationale: The paper states that the cohort comprised 186 participants and that a phylogenetic tree was built using all 186 sequences. This indicates that all individuals in the study underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The methods section explicitly states that all 186 participants were treatment-naïve at the time of sequencing.

Answer: Yes
"""

"""
Question: 4102

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The paper specifies that the study population consisted entirely of treatment-naïve individuals. There is no mention of any ART-experienced individuals.

Answer: No
"""

"""
Question: 4103

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The cohort is described as being exclusively composed of treatment-naïve individuals. There are no ART-experienced individuals included.

Answer: No
"""

"""
Question: 4104

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The paper explicitly states that all 186 participants were treatment-naïve.

Answer: 186
"""

"""
Question: 4105

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The paper provides a clear and consistent statement that all participants were treatment-naïve. It does not provide detailed individual ART histories because there was no prior ART to report.

Answer: Yes
"""

"""
Question: 4201

Evidence: Transmitted drug resistance (TDR) was present in 16/186 (8.6%) participants.

Rationale: The paper directly reports on the prevalence of Transmitted Drug Resistance (TDR) in the study population, which was 8.6%.

Answer: Yes
"""

"""
Question: 4202

Evidence: Transmitted drug resistance (TDR) was present in 16/186 (8.6%) participants.

Rationale: In the context of this study, which involves treatment-naïve individuals with primary infection, "Transmitted Drug Resistance" (TDR) is synonymous with "Pretreatment HIV Drug Resistance".

Answer: Yes
"""

"""
Question: 4301

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: As all participants were treatment-naïve at the time of sample collection, none of them had received any antiretroviral drug classes prior to sequencing.

Answer: None (All participants were treatment-naive)
"""

"""
Question: 4302

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: All participants were treatment-naïve, meaning they had not received any antiretroviral drugs, including integrase inhibitors.

Answer: No
"""

"""
Question: 4303

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: All participants were treatment-naïve, meaning they had not received any antiretroviral drugs, including protease inhibitors.

Answer: No
"""

"""
Question: 4304

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: Since all participants were treatment-naïve at the time of sequencing, none of them had received any ART.

Answer: Yes
"""

"""
Question: 4305

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: All participants were treatment-naïve, which means they were naive to all antiretroviral drug classes, including integrase strand transfer inhibitors (INSTIs).

Answer: Yes
"""

"""
Question: 4403

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The participants were treatment-naïve at the time of sample collection for sequencing. The paper does not provide information on how many, if any, later went on to receive more than one ART regimen after diagnosis.

Answer: NA
"""

"""
Question: 4404

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The participants were treatment-naïve at the time of sample collection. The paper does not provide information on how many later went on to receive more than two ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: At the time of sequencing, all participants had received zero ART regimens, as they were treatment-naïve.

Answer: Yes
"""

"""
Question: 4406

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: At the time of sequencing, all participants had received zero ART regimens. Therefore, the statement that all received one ART regimen is false.

Answer: No
"""

"""
Question: 4501

Evidence: We studied 186 treatment-naïve participants with primary HIV-1"""
Question: 4501

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: All participants were treatment-naïve at the time of sample collection and sequencing. Therefore, none of them had received dolutegravir or any other antiretroviral drug prior to the study.

Answer: 0
"""

"""
Question: 4502

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: All participants were treatment-naïve at the time of sample collection and sequencing. Therefore, none of them had received darunavir or any other antiretroviral drug prior to the study.

Answer: 0
"""

"""
Question: 5101

Evidence: Transmitted drug resistance (TDR) was present in 16/186 (8.6%) participants.

Rationale: The paper reports that 16 out of 186 participants had Transmitted Drug Resistance (TDR), meaning they had one or more drug resistance mutations.

Answer: 16
"""

"""
Question: 5102

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with the additional RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I.

Rationale: The drug resistance analysis was focused on protease and reverse transcriptase inhibitors (NRTIs, NNRTIs, PIs) using the WHO 2009 list and additional RT mutations. There is no mention of testing for or reporting integrase inhibitor (INSTI) resistance mutations.

Answer: 0
"""

"""
Question: 5103

Evidence: Transmitted drug resistance (TDR) was present in 16/186 (8.6%) participants. NRTI [resistance] was present in 5 (2.7%) [participants].

Rationale: The paper reports the prevalence of resistance by drug class. TDF (tenofovir) is an NRTI. The paper states that NRTI resistance was found in 5 participants. It does not specify which specific NRTI mutations were found, so we cannot confirm if TDF-resistance mutations (e.g., K65R) were among them.

Answer: NA
"""

"""
Question: 5104

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with the additional RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I.

Rationale: The paper only reports on drug resistance for protease and reverse transcriptase inhibitors. There is no analysis, mention, or reporting of integrase inhibitor (INSTI) resistance mutations.

Answer: NA
"""

"""
Question: 6101

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing. Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list.

Rationale: The paper describes genotypic resistance testing (sequencing to identify mutations) but does not describe any phenotypic susceptibility tests being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper is based on genotypic (sequence-based) analysis. There is no mention of any phenotypic assays being conducted, and therefore no IC50, IC90, or similar values are reported.

Answer: No
"""

"""
Question: 6103

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper is based on genotypic (sequence-based) analysis. There is no mention of any phenotypic assays being conducted, and therefore no IC50 fold change values are reported.

Answer: No
"""

"""
Question: 6104

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper does not utilize or report any phenotypic susceptibility assays. All resistance data is derived from genotypic sequencing.

Answer: NA
"""

"""
Question: 6105

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper focuses on transmission clusters, subtypes, and genotypic drug resistance. There is no mention of experiments measuring viral replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: Pol sequences (containing the full-length protease and the first 330--335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing.

Rationale: The paper does not describe any phenotypic drug susceptibility testing being performed. Therefore, no drugs were tested using such an assay.

Answer: NA
"""

"""
Question: 7101

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The viruses sequenced in this study were obtained directly from the plasma of infected individuals. There is no description of creating or studying viruses with site-directed mutations.

Answer: No
"""

"""
Question: 7102

Evidence: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-­ for-­ profit sectors.

Rationale: I have reviewed the entire paper content. The study involves the analysis of clinical samples from patients with primary infection. There is no description of any in vitro passage experiments being conducted.

Answer: No
"""